 "Dr Reddy's")
Shares of Dr Reddy’s Laboratories were up 3% at Rs 2,346 per share on the BSE after the company announced today that it has received final approval from the US Food and Drug Administration (USFDA) for the launch of Buprenorphine and Naloxone sublingual film in the US market.
In past eight trading sessions, the stock of pharmaceutical company has rallied 20% from Rs 1,960 on June 5, 2018, as compared to 2% rise in the S&P BSE Sensex.
“The company has received final approval from the (USFDA) and is launching Buprenorphine and Naloxone sublingual film, 2 mg/0.5 mg,
In past eight trading sessions, the stock of pharmaceutical company has rallied 20% from Rs 1,960 on June 5, 2018, as compared to 2% rise in the S&P BSE Sensex.
“The company has received final approval from the (USFDA) and is launching Buprenorphine and Naloxone sublingual film, 2 mg/0.5 mg,
